Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 10/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13929237 | 0.94 | SIGMAR1 (0.55) | SIGMAR1TSHRPKMOPRM1 | |
| SCHEMBL13929270 | 0.93 | SIGMAR1 (0.55) | SIGMAR1OPRM1 | |
| SCHEMBL13929241 | 0.93 | SIGMAR1 (0.51) | SIGMAR1TSHRPKMOPRM1ALDH1A1 | |
| SCHEMBL13929235 | 0.90 | PKM (0.49) | SIGMAR1TSHRPKMOPRM1 | |
| SCHEMBL13929296 | 0.90 | SIGMAR1 (0.58) | SIGMAR1TSHRPKMOPRM1 | |
| SCHEMBL13929310 | 0.90 | SIGMAR1 (0.58) | SIGMAR1TSHRPKMOPRM1 | |
| SCHEMBL13929263 | 0.90 | PKM (0.54) | SIGMAR1TSHRPKMOPRM1 | |
| SCHEMBL13929247 | 0.88 | PKM (0.48) | SIGMAR1TSHRPKMOPRM1 | |
| SCHEMBL13929239 | 0.88 | PKM (0.52) | SIGMAR1TSHRPKM | |
| SCHEMBL13929242 | 0.87 | SIGMAR1 (0.51) | SIGMAR1TSHRPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054451-A1 | Use of Piperidine Derivatives as Agonists of Chemokine Receptor Activity | EUROSCREEN S.A. (BE) | 2009-02-26 | — | — | US | disclosed |
| US-20090054451-A1 | Use of Piperidine Derivatives as Agonists of Chemokine Receptor Activity | EUROSCREEN S.A. (BE) | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054451-A1 | Use of Piperidine Derivatives as Agonists of Chemokine Receptor Activity | ACKR3, CCR5, CCR7 | SIGMAR1 129/4885TSHR 636/4885PKM 3209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.